Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Atox Bio 

Hi-Tech Park, Edmond J. Safra Campus
Givat-Ram, P.O. Box 39135
Jerusalem    91390  Israel
Phone: n/a Fax: 972-2-658-6689



 Company News
Atox Bio Announces Appointment Of Biotech Veteran Daniel D. Burgess As Chairman Of The Board 12/15/2014 8:39:11 AM
Atox Bio Awarded Contract Worth Up To $24 Million For The Development Of AB103 By The Biomedical Advanced Research and Development Authority (BARDA) 9/29/2014 7:10:21 AM
Atox Bio Release: AB103 Granted Orphan Medicinal Product Designation In The European Union For The Treatment Of Necrotizing Soft Tissue Infections (NSTI) 8/5/2014 7:15:54 AM
Atox Bio Locks In $23 Million 7/24/2014 6:11:02 AM
Atox Bio Reports Positive Tissue Infection Trial Results 11/20/2012 7:34:19 AM
FDA Grants Fast Track Designation to Atox Bio's AB103 for the Treatment of Necrotizing Soft Tissue Infections (NSTI) 9/10/2012 9:23:06 AM
Atox Bio Raises $3.25 Million to Advance Development of AB103, a Novel Therapy for the Treatment of Severe Bacterial Infections, Currently in Phase 2 Clinical Trials 12/19/2011 7:23:02 AM
Atox Bio Granted Orphan Drug Designation for AB103 for the Treatment of Necrotizing Soft Tissue Infections (NSTI) 10/25/2011 10:03:36 AM
Atox Bio Announces Successful Completion of Phase 1 for AB103, a Novel Immunomodulator Being Developed for Severe Bacterial Infections and Sepsis 5/12/2011 9:34:51 AM
Atox Bio Announces Dosing of the First Subject in Its Phase 1 Study of AB103 9/14/2010 12:30:20 PM